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1. Introduction
Rheumatic diseases are a group of illnesses characterized by the inflammation of the connec‐
tive tissue, usually of autoimmunological origin. Although most of the symptoms of the
rheumatic diseases concern primarily musculoskeletal system, in many of these disorders
pathological changes take also place in various other organs. Changes in the organ of sight
in the rheumatic diseases may result from the inflammatory process taking place in the
course of immunological dysfunctions and their manifestations may precede typical in these
illnesses musculoskeletal symptoms. Damage to the organ of sight may also be secondary to
vascular lesions occurring in the course of its inflammation or may be the result of complica‐
tions arising from the therapy of the rheumatic disease. (Table 1).
Rheumatic diseases with arthritis Rheumatoid arthritis
Spondyloarthropathies:
Ankylosing spondylitis
Psoriatic arthritis
Reactive arthritis
Arthritis associated with inflammatory bowel disease 
(Colitis ulcerosa, Leśniowski - Crohn's disease)
undifferentiated spondyloarthropathy
Juvenile idiopathic arthritis
Connective tissue diseases Systemic lupus erythematosus
Sjogren's syndrome
Systemic scleroderma
relapsing polychondritis
© 2013 Kwiatkowska and Maślińska; licensee InTech. This is an open access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Systemic vasculitis Polyarteritis nodosa
Churg-Strauss syndrome
Wegener's granulomatosis
Behçet's disease
Takayasu's disease
Giant cell arteritis
Cogan syndrome
Table 1. Rheumatic diseases with changes occurring in the organ of sight.
2. Characteristics of rheumatic diseases, in which the most frequent
changes in the organ of sight occur
The rheumatoid arthritis (RA) and spondyloarthropathies (SpA) are the most common in‐
flammatory rheumatic diseases. Significantly less frequently uvenile idiopathic arthritis
(JIA), Sjögren's syndrome (SS), systemic lupus erythematosus (SLE) and other less frequent
connective tissue diseases as scleroderma, dermato-and polymiositis, recurrent inflamma‐
tion of the cartilage and systemic vasculitis are observed.
2.1. Rheumatoid arthritis
Rheumatoid arthritis is an autoimmune connective tissue disease that manifests itself mostly
with symmetrical swelling of the joints (particularly of the hands) - and with morning stiff‐
ness. The incidence of RA in the world is estimated at about 0.33 -1.5% of the total popula‐
tion [1,2,3,4,5,6]. The diagnosis of RA is based on the current 2010 ACR / EULAR criteria.
The diagnosis of RA is definite when the summary point record for all criteria (A + B + C +
D) reaches ≥ 6 out of 10. (Table 2) [7].
A. Joint involvement 1 large joint
2-10 large joints
1-3 small joints (with or without involvement of large
joints )
4 - 10 small joints (with or without involvement of
joints )
"/ 10 joints (at least 1 small joint affected)
0
1
2
3
5
B. serological tests (at least one required) Negative results for the presence of RF and ACPA
Positive results in the presence of low-titer RF and
ACPA
Positive results in the presence of high titers of RF
and ACPA
0
2
3
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C. indicators of acute fase ( at least one required) Valid values for CRP and ESR
Incorrect values of CRP and ESR
0
1
D. duration of symptoms <6 weeks
≥ 6 weeks
0
1
RF – Rheumatoid Factor, ACPA – Anti-Citrullinated Protein Antibodies, CRP – C-Reactive Protein, ESR – Erythrocyte
Sedimentation Rate
Table 2. ACR/EULAR 2010 classification criteria for rheumatoid arthritis
Approximately 40% of patients with RA present not only joint inflammation but also clinical
symptoms resulting from other organ involvement [8].
Frequently, in as many as about 30% of patients with rheumatoid, rheumatoid nodules oc‐
cur [9]. The changes in the lungs, such as pleural involvement, take place in approximately
50% of patients, but only in 10% of cases are identified [10]. Similarly frequently autopsy re‐
veals changes in the heart.
In echocardiography pericardial effusion is revealed in 31% of patients [11]. 1 - 5% of patients
with RA are diagnosed with vasculitis, while autopsy studies detect these changes in 15-31% of
patients [12,13]. Changes in the eyes in the course of RA are observed in approximately 25% of
patients [14, 15]. The treatment of RA is based on disease-modifying drugs (DMARDs) such as
methotrexate,  sulfasalazine.  leflunomide,  cyclosporine,  cyclophospamide,  hydroxychloro‐
quine or chloroquine and gold salts. Furthermore, patients often have glucocorticoids and non-
steroidal anti-inflammatory drugs (NSAIDs) administered orally or locally (intra-articularly).
In the contemporary rheumatology in case of ineffectivness of the traditional DMARDs thera‐
py second line treatment is implemented - based on biological agents. These include TNF-
alpha (tumor necrosis factor) inhibitors such as adalimumab, certolizumab pegol, etanercept,
golimumab, infliximab as well as drugs with other mechanism of action such as abatacept (anti-
CTL-4), rituximab (anti-CD 20) and tocilizumab (anti-IL-6) [16].
Figure 1. Scleromalacia perforans in patient with long-term RA (photo by D. Kopacz).
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Figure 2. Scleromalacia perforans in patient with long-term RA (photo by D. Kopacz).
2.2. Spondyloarthropathies
Spondyloarthropathies (SpA) are a group of diseases are characterized by similar clinical
symptoms and genetic predispositions.
Table 3. ASAS classification criteria for axial spondyloarthropathy
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Spondyloarthropathies can be divided into 2 groups according to the predominant symp‐
toms. The domination of symptoms suggestive of spinal involvement, such as inflammatory
back pain (IBP) - i.e. pain escalating at night, decreasing after exercise, not alleviated by the
period of rest - defines axial spondyloarthropathy. In patients with prevalence to enthesitis
and peripheral arthritis, the peripheral sopndyloarthropathy is diagnosed. ASAS Group
(Ankylosing spondylitis In Assessment) has developed diagnostic criteria common to these
diseases (Table 3.4) [17, 18].
Peripheral arthritis (most commonly of the lower extremities and/or asymmetrical) or enthesitis (enthesitis), or
sausage fingers (dactylitis)
AND
≥ 1 symptom of SpA ≥ 2 other symptoms SpA
- Psoriasis - arthritis
- Crohn's disease-Lesniewski / colitis ulcerosa or - inflammation of the tendon
- Prior to infection - dactilitis , sausage fingers
- presence of HLA-B27 antigen - inflammatory back pain (ever)
- Uveitis - a history of SpA in the family
- Inflammation of the sacroiliac joints
   in imaging tests (X-ray or MRI)
Table 4. ASAS classification criteria for peripheral spondyloarthropathy
There separate classification criteria for particular spondyloarthropathies such as ankylosing
spondylitis (AS), psoriatic arthritis (PsA), reactinve arthritis (ReA), arthritis in course of ul‐
cerative colitis and Leśniowski- Crohn's disease are also established.
Spondyloarthropathies incidence is similar to that of RA and ranges from 0.15 to 1.8% of the
general population [19,20,21].
The uveitis affects approximately 0.5% of patients with spondyloarthropathies, and frequen‐
cy of its occurence varies depending on the type of spondyloarthropathies. In AS uveitis oc‐
curs in 0.8% of patients, while in about 2.3% of patients with the PsA [22]. Ocular changes in
SpA related to non-specific inflammatory bowel disease (ulcerative colitis, Leśniowski
Crohn's disease) occur in up to 4-12% of patients [23,24].
Conjunctivitis occurs in 33-100% of patients with reactive arthritis [25] and 20 to 33% of pa‐
tients with PsA [26].
The treatment of spondyloarthropathies is based on non-steroidal anti-inflammatory drugs,
disease-modifying drugs such as methotrexate, leflunomide, sulfasalazine, cyclosporyna
and biological agents from the group of anti-TNF-alpha. The glucocorticoids are also used in
intraarticular injections [27,28].
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2.3. Juvenile idiopathic arthritis
Juvenile idiopathic arthritis is the most common form of chronic inflammation of the con‐
nective tissue in children. Prevalence in the population is 43-148 cases per 100 000 persons
[29,30,31]. The diagnosis of JIA is based on the 1997 ILAR criteria. For the arthritis do be di‐
agnosed as JIA the onset of the disease must take place until 16 years of age, arthritis symp‐
toms must last more than 6 weeks and other diseases in which arthritis occurs have to be
excluded ( e.g.infectious, reactive, toxic and allergic and neoplastamatic diseases and other
conditions with joint involvment). Ocular complications - mainly uveitis - occur in approxi‐
mately 12-17% of juvenile patients [32]. Treatment, as in RA, is based on DMARDs and bio‐
logical agents.
2.4. Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with
diverse symptomatology resulting from involvement of many organs and systems. The prev‐
alence of SLE in the general population ranges from 0.016 to 0.092% [33,34,35]. The typical
clinical features of SLE include facial erythema, discoid rash, photosensitivity, oral ulcers,
arthritis,  pleurisy or pericarditis,  kidney changes, changes in the central nervous system,
haematological disorders (such as hemolytic anemia, leukopenia, lymphopenia, thrombocy‐
topenia), immune changes with presence of antinuclear, anti-DNA and anti-Sm autoantibod‐
ies, as well as false positive syphilis tests. SLE may be associated with antyphospolipid syndrome
(APS) with thrombotic episodes in the arteries and veins and obstetrics failure in women.
Diagnosis is based on the revised 1997 ACR classification criteria [36]. Changes in the organ
of sight occur in approximately 25% of patients, mainly in the course of secondary Sjögren's
syndrome but also as result of vasculitis and thrombosis [37]. Conjunctivitis, episcleritis and
interstitial keratitis are rare [38].
2.5. Primary Sjögren's syndrome
Primary Sjögren's syndrome (pSS) is an inflammatory autoimmune disease that occurs most
often in women between 40 and 50 years of age. The clinical symptoms of the disease result
from B cell autoreactivity, polyclonal immunoglobulin overproduction and infiltration of
exocrine glands by lymphocytes (CD4 cells predominate). The dominant symptom is dry‐
ness of the mouth and eyes. The nonerosive arthritis, vasculitis, peripheral neuropathy and
different symptoms from central nervous system are also observed in pSS. According to dif‐
ferent data Sjögren's syndrome prevalence rate ranges from 0.2 to 13.3% of the population
[39,40,41]. Sjögren's syndrome is diagnosed on the basis of the revised 2002 American-Euro‐
pean criteria[42]. Ocular symptoms associated with impaired secretion of tears occur in all
patients with Sjögren's syndrome – either in the initial or more advanced stages of the dis‐
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ease – and constitute one of to the diagnostic criteria. Treatment is based on the use of both
symptomatic drugs - moistening eyes and mouth – and of immunosuppressants.
2.6. Scleroderma
Scleroderma is an inflammatory connective tissue disease of unknown etiology character‐
ized by the damage to blood vessels, the presence of autoantibodies (SCL 70 or anticen‐
tromeric  autoantibodies  for  diffuse  systemic  sclerosis  and  localised  systemic  sclerosis
respectively)  and progressive fibrosis  of  the skin and internal  organs.  Systemic sclerosis
prevalence rate in the world is ranging from 0.0007% to 0.265% [43,44,45].  Disease diag‐
nosis  based  on  the  classification  and  diagnostic  criteria  of  the  1980  ACR  [46].  71%  of
patients present changes in blood and conjunctival subepithelial fibrosis. In course of SS
all  structures  of  the  eye  may  be  affected  [47,48].  Patient  with  SS  may  develop  secon‐
dary Sjogren's syndrome and symptoms of dry eye, as well  as complications due to the
dryness of the conjunctiva [49].
2.7. Recurrent inflammation of the cartilage
Recurrent inflammation of the cartilage is a rare inflammatory autoimmune disease in
which the inflammatory process involving mostly cartilage, causing changes and dysfunc‐
tion of many tissues and organs. Onset of the disease usually affects people of 40-60 years of
age and the prevalence of this disease in the world is estimated at about 3 cases per 1 million
people in the population [50]. Currently, the diagnosis of this disease can be based on the
diagnostic criteria of McAdam, 1976 [51]. Changes in the organ of vision occur in approxi‐
mately 60% of patients and may include almost all structures of the eye [52, 53].
2.8. Systemic vasculitis
In the course of systemic vasculitis such as polyarteritis nodosa, Churga-Strauss syndrome,
Wegener's granulomatosis, Behçet's disease, Takayasu disease, giant cell arteritis and Cogan
syndrome there are changes in the organ of sight secondary to vascular changes. In polyarteri‐
tis nodosa ocular changes are observed in approximately 10-20% of patients [54,55], in Wegen‐
er's granuloma in 28-58% of patients [56,57] Behçet's disease in 68-85% of patients [58, 59, 60].
The ocular changes in course of inflammation of the large vessels, such as giant cell arteritis, are
mainly associated with ischemia of optic nerve or retina. Ischemia causes impairment of vision
and blindness, which may occur in 13 to 70% of patients [61,62]. The treatment of all systemic
vasculitis requires agressive immunosuppressive therapy and high doses of glucocorticoids. In
some cases of very active disease and no reaction to other treatment, especially in case of Wegener's
granuloma, biological therapy (rituximab) is used [63,64]
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3. Characteristic changes in the organ of sight in rheumatic diseases
The pathological changes can occur in all elements of the organ of sight in the course of rheumatic
diseases. These can cause temporary or permanent damage (Table 5). Changes in the eyes are
the first symptom of rheumatic fever observed in approximately 4% of patients [65].
type of symptoms and changes in the eye rheumatic disease
conjunctivitis Reactive arthritis
Psoriatic arthritis
dryness Sjögren's syndrome
Rheumatoid vasculitis
Rheumatoid arthritis
Systemic vasculitis
Uveitis:
Acute anterior uveitis
Chronic anterior uveitis
Panuveitis
Spondyloarthropathies
Behçet disease
colitis ulcerosa/ Leśniowski - Crohn's disease
colitis ulcerosa/ Leśniowski-Crohn;s disease
relapsing polychondritis
Behçet disease
Scleritis Rheumatoid arthritis
systemic vasculitis
Colitis ulcerosa/ Leśniewski- Crohn;s disease
Relapsing polychondritis
Keratitis:
Non-necrotizing corneal melt
Necrotizing keratitis
Sjögren's syndrome
Rheumatoid vasculitis
Rheumatoid arthritis
systemic vasculitis
Retinal vasculopathy
Microvasculopathy
Diffuse vaso-occlusive disease
Systemic Lupus erythematosus
Systemic lupus erythematosus
Antiphospholipid syndrome
Behçet disease
Optic nerve disaease
Ischemic optic neuropathy
Systemic vasculitis (particulary giant cell vasculitis)
Table 5. The most common ocular changes in the course of the rheumatic diseases.
Changes in the eyes in course of the rheumatic diseases may also be caused by the imple‐
mented treatment. Nonsteroidal anti-inflammatory drugs are medications most commonly
used in alleviating the symptoms of rheumatic diseases. Cases of keratopathy (keratopathy)
after indomethacin use have been reported [66], and diplopia (double vision) and amblyopia
(amblyopia) after ibuprofen and naproxen treatment [67]. Antimalaric drugs such as hy‐
droxychloroquine and more often chloroquine may aggregate in the cornea [68], in 13 - 40%
of patients causing retinopathy [69,70]. Gold salts - administered parenterally over the total
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dose of 1000mg/kg of body weight – accumulate in various tissues of the body and have
been observed in the eyes (conjunctiva, cornea, anterior lens and retina) in 97% of patients
[71]. Gold salt deposits in the eyes may cause hypersensitivity reactions, induce inflamma‐
tion and cause marginal ulceration [72]. After methotrexate therapy diffuse irritation of the
cornea is observed [73]. Chronic glucocortycoid therapy often leads to cataracts, subcapsular
cataracts and glaucoma [74, 75].
4. Infectious complications of the eyes in rheumatic diseases
Viral, bacterial and fungal infectious complications occur in the organ of sight in patients
with rheumatic diseases more frequently than in healthy individuals due to the immunolog‐
ical system dysfunctions, immunosuppressive therapy and chronic use of corticosteroids.
4.1. Infective conjunctivitis
4.1.1. Bacterial conjunctivitis
Chlamydial conjunctivitis
Reactive arthritis, which belongs to spondyloarthropaties, may be caused by infection with
Chlamydia trachomatis and Chlamydia pneumoniae [76]. In the course of the infection with
Chlamydia trachomatis (serotypes DK) chronic conjunctivitis occurs in 6-19% of patients [77,
78]. Chlamydial conjunctivitis most commonly affects sexually active adults, especially men.
Chlamydia DNA is detected by PCR (polymerase chain reaction) in 96% of patients with re‐
active arthritis concomitant conjunctivitis, leakage from the urethra and inflammation of
asymmetric arthritis (former name of these symptoms is Reiter's syndrome) [79]. Eye in‐
volvement probably occurs by the way of self infection from the genitourinary system, or
from one eye to another. In chlamydial conjunctivitis in adults symptoms initially occur in
one of the eyes. It was also found that conjunctivitis may also occur (less frequently than in
Chlamydia trachomatis) in the course of Chlamydia pneumoniae infection – as was demon‐
strated by confirming the presence of bacterial DNA from conjunctival scraping [80].
Clinical symptoms of chlamydial conjunctivitis in reactive arthritis are characterized by
moderate redness of a single eye or less commonly of both eyes, tearing, photophobia and
decreased vision. Ocular examination shows conjunctival hyperemia, chemosis and follicu‐
lar reaction in conjunctiva and semilunar folds. Epithelial and subeopithelial infiltrates in
cornea may develop.
The histopathology assessment reveals the presence of the chronic inflammation cells local‐
ized in submucosal layer, with the predominance of lymphocytes. In addition, fibrinogen
deposits in the basal membrane of conjunctiva, infiltration of lymphocytes and macrophages
around small blood vessels and lymphocytic infiltration of the walls of larger vessels of con‐
junctiva have been observed [81].
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Diagnosis is based on the detection of IgM, IgG and IgA antibodies to these bacteria in the
blood serum by ELISA method and confirmation with W-blot test. Classical method is a
detection of  Chlamydia  basophilic  intracytoplasmic  inclusions  in  primary cells  from the
conjunctival swab or conjunctival scraping using DFA (direct immunofluorescence stain‐
ing) method, DNA hybridization tests or PCR (polymerase chain reaction and LCR (Ligas
chain reaction).
Treatment of chlamydial conjunctivitis infection in the course of reactive arthritis consists of
systemic antibiotic therapy and topical use of tetracycline, erythromycin or fluorochino‐
lones. In systemic treatment effectiveness of macrolides (azithromycin), tetracyclines and
quinolones has been shown [82,83, 84]. Single dose of azithromycin (1000mg) showed effica‐
cy in eradication of C. trachomatis infection [85] It's vital to stress that chlamydia infection is
still the main cause of blindness on the African Continent. In the case of trachoma present
drug of choice is azithromycin [86].
Because C.trachomatis infection is sexually transsmitted, other similarly transmitted co- in‐
fections should be considered, most commonly gonococcal.
4.1.2. Fungal conjunctivitis
Significantly higher incidence of fungal conjunctivitis is observed in patients with rheumatic
diseases treated with systemic glucocorticoids (eg, RA) and in patients with primary Sjögren's
syndrome. The most common pathogens are Candida albicans and Candida parapsilosis [87].
5. Infectious scleritis in rheumatic diseases
It has been shown that in patients with scleral inflammation lasting over 12 years, 7.5% of
them had infectious complications, usually caused by herpes zoster virus [88]. Infectious
complications can be even more frequent in patients with rheumatic diseases who are chron‐
ically treated with immunosuppressive drugs. The use of immunosuppressive drugs can
cause reactivation of latent Mycobacterium tuberculosis infection which, in the form of nod‐
ular scleritis may occur in the eye [89]. There are reports of the occurrence of tuberculosis
uveitis during treatment with etanercept (soluble anti TNF inhibitor) [90].
6. Infectious keratitis in rheumatic diseases
6.1. Viral keratitis
In RA patients inflammatory corneal ulceration may occur as a symptom of this disease. How‐
ever,  any such changes require  the differentiation from herpes  simplex infection,  which
presents the same clinical picture. The differentiation is important from the point of imple‐
mented treatment, because corneal ulceration in course of RA requires a very intensive immu‐
nosuppressive  therapy,  which  exacerbates  an  inflammation  caused  by  herpes  simplex
infection [91].
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6.2. Bacterial keratitis
Bacterial keratitis in rheumatic diseases often is a complicated by erosive lesions of the cor‐
nea. Such changes are most commonly associated with primary and secondary Sjögren's
syndrome. Most frequently - up to 73.9% - patients suffer from Gram-positive bacterial in‐
fections of as coagulase-negative Staphylococci, Staph. aureus and Spreptococcus pneumo‐
niae. 0.3% of patients suffer from infections of Gram-negative Moraxella spp. Infections with
Gram-positive bacteria are present in 17.4% of patients; most common are : Propionibacteri‐
um acnes, Corynebacterium spp. 6.5% patients reveal infections caused by Pseudomonas
aeruginosa and Proteus spp [92,93].
6.3. Fungal keratitis
The fungal infections of the cornea may also develop in the primary and secondary Sjogren's
syndrome due to improper hydration of the eye – both because of the composition of tears and
rupture in the tear film. In 45.8% of patients with fungal infection of the cornea Candida albi‐
cans is the major pathogen, while Fusarium spp accouns for approximately 25% of the infec‐
tions.
7. Comment
In the light of the wide use of immunosuppressive therapy, in particular in the era of biolog‐
ical therapies in rheumatic diseases, close attention should be paid to the possible reactiva‐
tion of latent infections. Most commonly tuberculous infection should be considered, but
viruses like Cytomegalovirus (CMV) may also be present in patients in their persistent form.
In similar circumstances - in AIDS patients and patients after organ transplantations (e.g.
bone marrow transpaltation) - CMV retinitis has been reported. Currently there are reports
of CMV retinitis in the course of treatment RA with infliximab (anti TNF) [94].
Finally, it should be noted that biological drugs have proved effective in the treatment of oc‐
ular manifestations of many rheumatic diseases and the exclusion of potential infection is
particularly important for the choice of treatment and safety of therapy.
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